| Type | Title | Author(s) | Year | Views |
| Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response | Ma, BBY; Lui, VWY; Poon, FF; Wong, SCC; To, KF; Wong, E; Chen, H; Lo, KW; Tao, Q; Chan, ATC | 2010 | 578 |
| |
| Erratum: Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response (Investigational New Drugs DOI: 10.1007/s10637-009-9316-7) | Ma, BBY; Lui, VWY; Poon, FF; Wong, SCC; To, KF; Wong, E; Chen, H; Lo, KW; Tao, Q; Ng, MHL; Cheng, SH; Chan, ATC | 2010 | 555 |
| |
| The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines | Ma, BBY; Lui, VWY; Hui, EP; Lau, CPY; Ho, K; Ng, MHL; Cheng, SH; Tsao, SW; Chan, ATC | 2010 | 355 |
| |
| STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro | Lui, VWY; Wong, EYL; Ho, Y; Hong, B; Wong, SCC; Tao, Q; Choi, GCG; Au, TCC; Ho, K; Yau, DMS; Ma, BBY; Hui, EP; Chan, ASK; Tsang, CM; Tsao, SW; Grandis, JR; Chan, ATC | 2009 | 305 |
| |
| Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas | Jin, H; Wang, X; Ying, J; Wong, AHY; Li, H; Lee, KY; Srivastava, G; Chan, ATC; Yeo, W; Ma, BBY; Putti, TC; Lung, ML; Shen, ZY; Xu, LY; Langford, C; Tao, Q | 2007 | 140 |
| |
| Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma | Sung, FL; Pang, RTK; Ma, BBY; Lee, MML; Shuk, MC; Poon, TCW; Chan, ATC | 2006 | 21 |
| |
